D
Aerovate Therapeutics, Inc. AVTE
$2.51 -$0.01-0.40%
Recommendation
Sell
Prev Close
$2.52
Volume
110,117
Avg Vol (90D)
153,293
Market Cap
$73.04M
Dividend & Yield
--
52-Week Range
$1.25 - $30.29
P/E (TTM)
--
EPS (TTM)
-$2.45
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AVTE, HEES, AMPY on Behalf of Shareholders
4/2/2025 - Globe Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AMPY, HEES, AVTE, TGI to Act
4/2/2025 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AVTE, HEES, AMPY on Behalf of Shareholders
4/1/2025 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AMPY, HEES, AVTE, TGI to Act Now
3/31/2025 - Globe Newswire
Aerovate Therapeutics (NASDAQ:AVTE) Issues Quarterly Earnings Results, Meets Expectations
3/29/2025 - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, AVTE, HEES on Behalf of Shareholders
3/26/2025 - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
3/23/2025 - Globe Newswire
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick ...
3/21/2025 - GuruFocus
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
3/21/2025 - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PTMN, AVTE on Behalf of Shareholders
3/20/2025 - PR Newswire
STOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - NHHS, KVAC, AMPS, AVTE
3/18/2025 - PR Newswire
Aerovate Therapeutics (AVTE) Expected to Announce Quarterly Earnings on Monday
3/17/2025 - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders
2/25/2025 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - CCNE, LGTY, AVTE, PLYA
2/24/2025 - PR Newswire
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update
2/17/2025 - MarketBeat
Deltec Asset Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
2/6/2025 - MarketBeat
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 35.5% in January
1/31/2025 - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTS, AVTE, MHLD, IPG on Behalf of Shareholders
1/24/2025 - PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - IPG, VTS, AVTE, MHLD
1/24/2025 - PR Newswire
Aerovate Therapeutics (NASDAQ:AVTE) and Bioxytran (OTCMKTS:BIXT) Financial Comparison
1/19/2025 - Ticker Report
Stock Traders Buy High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)
1/17/2025 - MarketBeat
Stock Traders Purchase High Volume of Aerovate Therapeutics Call Options (NASDAQ:AVTE)
1/17/2025 - Ticker Report
Jane Street Group LLC Trims Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
1/17/2025 - MarketBeat
Jane Street Group LLC Sells 109,358 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
1/17/2025 - Ticker Report
Noteworthy Thursday Option Activity: CNX, AVTE, CRC
1/16/2025 - Stock Options Channel
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$74.31M
EBIT (TTM)
-$74.60M
Net Income (TTM)
-$69.63M
Balance Sheet
Total Assets (Q)
$80.33M
Total Debt (Q)
$417.00K
Total Liabilities (Q)
$3.90M
Book Value Per Share (Q)
$2.64
Cash Flow
Cash from Operations (TTM)
-$71.20M
Cash from Investing (TTM)
$56.03M
Cash from Financing (TTM)
$25.43M
Net Change in Cash (TTM)
$10.26M
Filings
Filing Date
Monday, February 24, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
1.08
7-Day Total Return
0.00%
30-Day Total Return
5.02%
60-Day Total Return
-7.04%
90-Day Total Return
-5.64%
Year to Date Total Return
-6.52%
1-Year Total Return
-91.38%
2-Year Total Return
-87.13%
3-Year Total Return
-84.47%
5-Year Total Return
--
52-week Low
Jun 20, 2024 - $1.25
52-week High
Apr 04, 2024 - $30.29
Valuation
Market Cap
$73.04M - Micro Cap
Enterprise Value
-$5.16M
Price/Sales (TTM)
--
Price/Book (Q)
0.96
Dividends and Shares
Shares Outstanding
28.61M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
aerovatetx.com
Phone Number
617 443 2400
Address
930 Winter Street
Waltham, MA 02451
Country
United States
Year Founded
2018
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on... more
NASDAQ 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings